Rani Therapeutics Holdings Inc. (RANI) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Rani Therapeutics Holdings Inc. (RANI:NASDAQ), powered by AI.

Current Price
$0.76
Sector
Healthcare
What is the Rani Therapeutics Holdings Inc. stock price forecast?

Rani Therapeutics Holdings Inc. is currently trading at $0.76. View real-time AI analysis on Alpha Lenz.

What is Rani Therapeutics Holdings Inc. insider trading activity?

View the latest insider trading data for Rani Therapeutics Holdings Inc. on Alpha Lenz.

What is Rani Therapeutics Holdings Inc.'s P/E ratio?

View Rani Therapeutics Holdings Inc.'s valuation metrics on Alpha Lenz.

Rani Therapeutics Holdings Inc.

NASDAQ · RANI
$0.76-0.04(-5.22%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Rani Therapeutics Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Rani Therapeutics Holdings Inc.'s ROE is -169.6%. Explore profitability and growth together.

Ask for details

Company Overview

Rani Therapeutics Holdings Inc. is a pioneering entity in the biopharmaceutical field, dedicated to transforming the delivery of biologics and other macromolecules. The company endeavors to address challenges associated with the oral administration of biologic drugs, which are typically delivered through injections, by developing the RaniPill capsule. This innovative technology is designed to enable the oral delivery of these complex drugs, significantly impacting how treatments can be administered for chronic diseases such as diabetes, rheumatoid arthritis, and other autoimmune disorders. Operating at the intersection of pharmaceuticals and cutting-edge medical technology, Rani Therapeutics stands as a disruptive force within the healthcare sector, aiming to enhance patient compliance and expand market access for critical therapies. Established to advance healthcare delivery, the company's work holds potential significance for pharmaceutical manufacturers, healthcare providers, and patients, offering a unique solution to a long-standing challenge in the medical industry. As Rani Therapeutics Holdings Inc. continues its pursuit of novel drug delivery methods, it remains an important player in the biopharmaceutical innovation landscape.

CEOMr. Talat Imran
SectorHealthcare
IndustryBiotechnology
Employees105

Company Statistics

FY 2025

Profile

N/AMarket Cap
$1.63MRevenue
0.00Shares Out
105Employees

Margins

N/AGross
-2240.23%EBITDA
-2345.99%Operating
-2507.65%Pre-Tax
-2507.65%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
28.73%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-85.98%ROA
-169.55%ROE
-79.91%ROIC

Financial Health

$18.62MCash & Cash Equivalents
$-1.51MNet Debt
41.21%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Rani Therapeutics Holdings Inc. (ticker: RANI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 105 employees.

The current price is $0.76 with a P/E ratio of -x and P/B of -x.

ROE is -169.55% and operating margin is -2345.99%. Annual revenue is $2M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Rani Therapeutics Holdings Inc. (RANI) Stock Forecast 2026 $0.76 — Price, Financials & Analyst Targets | Alpha Lenz